Introduction

i'm delighted to welcome jason carlowish to the podcast. Jason is the co director of the pen memory center at the university of pennsylvania. The title of that essay is, aducan mab and the business of alsheimer disease. There's been a lot of controversy about this drug's approval,. including the f d a's decision to allow a reduction in bata ameloid as a circuit marker through this accelerated approval pathway. i encourage you to check out the august neurology recall.